Biomarkers used for medicine, or precision medicine, are a part of a relatively new clinical toolset. They are categorized in 3 primary ways according to their clinical applications. They are classified as molecular biomarkers, cellular biomarkers or imaging biomarkers. All 3 types of biomarkers have a clinical role in narrowing or guiding treatment decisions and follow a sub-categorization of being predictive, prognostic, or diagnostic. A case-control design was used to test the association of gene expression with outcome. Systemic (SYS) progression cases were men post-prostatectomy who developed systemic progression within 5 years after PSA recurrence. PSA progression controls were matched men post-prostatectomy with PSA recurrence but no evidence of clinical progression within 5 years. Using expression arrays optimized for paraffin-embedded tissue RNA, cancer-related genes were evaluated–including 570 genes implicated in prostate cancer progression. Genes from 8 previously reported marker panels were included. A systemic progression model containing 17 genes was developed. This model generated Similar AUCs were generated using 3 previously reported panels. In secondary analyses, the model predicted the endpoints of prostate cancer death with hazard ratios and respectively
Select your language of interest to view the total content in your interested language
Research & Reviews in BioSciences received 534 citations as per Google Scholar report
Read More